Abstract
Aim To further explore the association between Transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 T/C gene polymorphism and hepatic fibrosis.
Materials and Methods In this study the MEDLINE, PubMed, EMBASE, and CENTRAL databases were queried from inception to March 21, 2020. According to inclusion and exclusion criteria, case-control studies assessing the relationship between TM6SF2 rs58542926 T/C gene polymorphism and significant liver fibrosis were selected. NOS scale was used to evaluate the included literature. Stata 12.0 software was used for data analysis.
Results In this meta-analysis,a total of 7 articles, including 2286 patients were included. Statistical analysis showed that the TM6SF2 gene polymorphism was associated with significant liver fibrosis in the allele contrast, recessive dominant models (T vs. C, OR=1.292, 95%CI 1.035-1.611, P=0.023; TT vs. CT+CC, OR=2.829, 95%CI 1.101-7.267, P=0.031). No significant publication bias was found after Egger’s test.
Conclusion The present findings suggest that the TT genotype and T gene of TM6SF2 rs58542926 T/C gene polymorphism are associated with susceptibility to significant hepatic fibrosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
There is nothing suitable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict-of-interest statement:The authors have no conflict of interest to declare. There are no financial or other competing interests for principal investigators, the patients included, or any trial participant.
Funding:This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data Availability
All the data mentioned in the manuscript are available.
Abbreviations
- TM6SF2
- transmembrane 6 superfamily member 2
- HCC
- hepatocellular carcinoma
- NAFLD
- nonalcoholic fatty liver disease
- HCV
- hepatitis C virus
- PSC
- primary sclerosing cholangitis
- CHC
- chronic hepatitis c
- CHB
- chronic hepatitis b
- ALD
- alcoholic fatty liver disease
